Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer

We assumed that the effect of adjuvant trastuzumab on survival is mediated by the treatment time and we conducted this trial-level meta-regression to determine the appropriate length of treatment. Twelve adjuvant trastuzumab trials (from January 2000 to June 2019, consisting of 20,271 patients) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ke-Da, Wang, Xin, Chen, Wan-Kun, Fan, Lei, Mo, Miao, Chen, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406512/
https://www.ncbi.nlm.nih.gov/pubmed/32802960
http://dx.doi.org/10.1038/s41698-020-00128-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406512/
https://www.ncbi.nlm.nih.gov/pubmed/32802960
http://dx.doi.org/10.1038/s41698-020-00128-1

Ejemplares similares